Login / Signup

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.

Elisa AgostinettoDaniel EigerKevin PunieEvandro de Azambuja
Published in: Current oncology reports (2021)
Emerging therapies are forthcoming in TNBC's treatment landscape, including new post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates. Combination of different therapies such as AKT/PI3K/mTOR-inhibitors, other immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, and histone deacetylase inhibitors is under clinical investigation. The treatment landscape for TNBC is gradually evolving towards a more personalized approach with promising expectations.
Keyphrases
  • neoadjuvant chemotherapy
  • histone deacetylase
  • cell proliferation
  • single cell
  • signaling pathway
  • dna damage
  • small molecule
  • squamous cell carcinoma
  • drug delivery
  • combination therapy